This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ABIOMED Gets FDA Confirmation of the Safety of Impella RP
by Zacks Equity Research
ABIOMED (ABMD) receives the FDA confirmation of the safety and effectiveness of the company's Impella RP heart pump.
Masimo Gets FDA Nod for Radius PPG, Boosts Patient Monitoring
by Zacks Equity Research
Masimo (MASI) receives FDA 510 (k) clearance for Radius PPG, which is set to become an important breakthrough in patient monitoring.
Here's Why You Should Retain Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex volatility remains a concern.
Here's Why You Should Retain DaVita (DVA) in Your Portfolio
by Zacks Equity Research
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, divestment of DMG segment might lower cash flows.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) is gaining steadily from its core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
QDEL vs. GNNDY: Which Stock Is the Better Value Option?
by Zacks Equity Research
QDEL vs. GNNDY: Which Stock Is the Better Value Option?
Quidel (QDEL) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Quidel (QDEL) delivered earnings and revenue surprises of -11.65% and -6.08%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Quidel (QDEL) Q1 Earnings Expected to Decline
by Zacks Equity Research
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured expert Kevin Matras highlights: Lululemon Athletica, Quidel, Kirkland Lake Gold and World Wrestling Entertainment
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Lululemon Athletica, Quidel, Kirkland Lake Gold and World Wrestling Entertainment
4 Must-Buy Efficient Stocks for Your Portfolio
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with the company's price performance.
Quidel (QDEL) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Quidel's (QDEL) flagship Triage sees strong growth in China in Q4.
Quidel (QDEL) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Quidel (QDEL) delivered earnings and revenue surprises of 29.03% and 0.32%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Quidel (QDEL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Quidel (QDEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Cardinal Health's (CAH) Q2 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q2; medical-gloves sub-segment likely to be soft.
Here's Why You Should Buy Express Scripts (ESRX) Stock Now
by Zacks Equity Research
Strong demand for Express Scripts' (ESRX) solutions like SafeGuardRx, 90-day supply for chronic medications, exclusive Accredo Specialty Pharmacy and advanced opioid solutions buoy optimism.
Here's Why You Should Hold Allscripts Stock in Your Portfolio
by Zacks Equity Research
Allscripts (MDRX) has been winning contracts in the Sunrise EHR platform; competition stiff.
Express Scripts Announces 3-Year Agreement With Walmart
by Zacks Equity Research
Express Scripts (ESRX) and Walmart (WMT) collaborate to increase affordable access of the expensive prescription drugs for insured and uninsured patients.
Quidel (QDEL) Catches Eye: Stock Jumps 6.7%
by Zacks Equity Research
Quidel (QDEL) shares rose nearly 7% in the last trading session, amid huge volumes.
BD Gets Enterprise Level Cybersecurity Assessment From UL
by Zacks Equity Research
BD (BDX) receives UL CAP for BD FACSLyric flow cytometer with BD FACSuite Clinical software.
Here's Why Investors Should Hold Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) gains from solid prospects in the SET Pulse Oximeter platform. However, cutthroat competition in the MedTech space is likely to hurt the stock.
Ecolab to Boost Food Safety Standards With Holchem Buyout
by Zacks Equity Research
Ecolab (ECL) to benefit from Holchem Group's unique offerings for the food and beverage, foodservice and hospitality industries.
Here's Why Investors Should Hold AngioDynamics Stock Now
by Zacks Equity Research
AngioDynamics' (ANGO) gains from solid prospects in the NanoKnife platform. However, sluggishness in the Venous Insufficiency business is a headwind.
Veeva Systems Announces New DAM Solution for Life Sciences
by Zacks Equity Research
Veeva Vault Digital Publishing uses Veeva Systems' (VEEV) flagship Vault PromoMats or Vault MedComms platforms for updating digital content. The platform leverages on Amazon CloudFront.
Here's Why You Should Hold Pacific Biosciences (PACB) Now
by Zacks Equity Research
Pacific Biosciences (PACB) is likely to gain from strong prospects in the Sequel System platform. However, the company faces cutthroat competition in the DNA sequencing market.
Here's Why You Should Invest in Accuray (ARAY) Stock Now
by Zacks Equity Research
Accuray's (ARAY) benefits from growing adoption of non-surgical treatment options among cancer patients and increasing demand for its latest offerings.